文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌与上尿路尿路上皮癌新辅助化疗疗效比较

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
PubMed 文献 · BJU Int · 2020-10-14

多中心研究纳入1299例膀胱癌和276例上尿路尿路上皮癌患者,比较新辅助化疗后的病理完全缓解率、客观缓解率及生存差异。上尿路患者病理完全缓解率更低(8.3% vs 19.2%,P<0.01),但客观缓解率更高(48.2% vs 40.3%,P=0.02),且癌症特异性生存更优(HR 0.61,95%CI 0.45-0.82)。

要点

  • 上尿路尿路上皮癌新辅助化疗后病理完全缓解率显著低于膀胱癌(8.3% vs 19.2%)。
  • 上尿路患者病理客观缓解率更高(48.2% vs 40.3%),提示整体缓解模式不同。
  • 上尿路患者癌症特异性生存更优(HR 0.61,95%CI 0.45-0.82,P<0.01)。

核心结论

  • 上尿路尿路上皮癌新辅助化疗的获益与膀胱癌相似,可作为生存结局参照和未来试验设计基准。

研究设计与样本

  • 多中心协作回顾性研究,纳入1299例膀胱癌和276例上尿路尿路上皮癌接受根治性手术的患者。

主要发现

  • 膀胱癌病理完全缓解250例(19.2%),上尿路尿路上皮癌23例(8.3%),P<0.01。
  • 膀胱癌病理客观缓解523例(40.3%),上尿路尿路上皮癌133例(48.2%),P=0.02。
  • 多因素logistic回归:上尿路患者病理完全缓解可能性更低(OR 0.45,95%CI 0.27-0.70,P<0.01),病理客观缓解可能性更高(OR 1.57,95%CI 1.89-2.08,P<0.01)。
  • 单因素Cox回归:上尿路与更好总生存相关(HR 0.80,95%CI 0.64-0.99,P=0.04)和癌症特异性生存相关(HR 0.63,95%CI 0.49-0.83,P<0.01)。
  • 多因素Cox回归:上尿路仍与癌症特异性生存相关(HR 0.61,95%CI 0.45-0.82,P<0.01),但与总生存无关。

临床怎么用

  • 上尿路尿路上皮癌新辅助化疗后病理完全缓解率较低但客观缓解率较高,评估疗效时需结合缓解模式。
  • 上尿路患者癌症特异性生存更优,可据此与患者沟通预后并设计后续临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the differential response to neoadjuvant chemotherapy (NAC) in patients with urothelial carcinoma of the bladder (UCB) compared to upper tract urothelial carcioma (UTUC) treated with radical surgery. PATIENTS AND METHODS: Data from 1299 patients with UCB and 276 with UTUC were obtained from multicentric collaborations. The association of disease location (UCB vs UTUC) with pathological complete response (pCR, defined as a post-treatment pathological stage ypT0N0) and pathological objective response (pOR, defined as ypT0-Ta-Tis-T1N0) after NAC was evaluated using logistic regression analyses. The association with overall (OS) and cancer-specific survival (CSS) was evaluated using Cox regression analyses. RESULTS: A pCR was found in 250 (19.2%) patients with UCB and in 23 (8.3%) with UTUC (P < 0.01). A pOR was found in 523 (40.3%) patients with UCB and in 133 (48.2%) with UTUC (P = 0.02). On multivariable logistic regression analysis, patients with UTUC were less likely to have a pCR (odds ratio [OR] 0.45, 95% confidence interval [CI] 0.27-0.70; P < 0.01) and more likely to have a pOR (OR 1.57, 95% CI 1.89-2.08; P < 0.01). On univariable Cox regression analyses, UTUC was associated with better OS (hazard ratio [HR] 0.80, 95% CI 0.64-0.99, P = 0.04) and CSS (HR 0.63, 95% CI 0.49-0.83; P < 0.01). On multivariable Cox regression analyses, UTUC remained associated with CSS (HR 0.61, 95% CI 0.45-0.82; P < 0.01), but not with OS. CONCLUSIONS: Our present findings suggest that the benefit of NAC in UTUC is similar to that found in UCB. These data can be used as a benchmark to contextualise survival outcomes and plan future trial design with NAC in urothelial cancer.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. D'Andrea D, Matin S, Black PC, et al. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2020. PMID: 32981193. doi:10.1111/bju.15253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。